Neucrylate

Neucrylate is a liquid embolic medical device developed by Valor Medical for the treatment of cerebral aneurysms and arteriovenous malformations (AVMs). The active component is 1-hexyl n-cyanoacrylate, a compound that functions as a moldable liquid embolic agent. During clinical application, it is typically injected into the vascular abnormality during temporary balloon occlusion of the parent vessel. The device contains a metal component to provide radiopacity for visualization under fluoroscopy. Neucrylate's regulatory path was terminated following a legal investigation where Valor Medical and its executives pleaded guilty to concealing adverse toxicity reports from the FDA during the premarket review process.

Brand names

Neucrylate

Other names

1-hexyl n-cyanoacrylate